期刊
ONCOTARGETS AND THERAPY
卷 9, 期 -, 页码 5943-5953出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S100515
关键词
leukemia; lymphoma; multiple myeloma; toxicity; resistance mechanisms
资金
- [R01CA186885]
- NATIONAL CANCER INSTITUTE [R01CA186885] Funding Source: NIH RePORTER
The bromodomain and extra-terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of critical oncogenes. BET inhibitors have been demonstrated to repress c-Myc expression, and were initially shown to have efficacy in a number of c-Myc-dependent hematologic malignancies. Recent studies have now revealed a broader role for BET inhibitors in hematologic malignancies. In this review, we summarize the efficacy of BET inhibitors in preclinical models of acute leukemia, lymphoma, and multiple myeloma. We also summarize recent results of clinical trials utilizing BET inhibitors in hematologic malignancies, characterize potential resistance mechanisms to BET inhibitors, and discuss potential combination therapies with BET inhibitors in patients with hematologic malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据